DOSE-FREQUENCY TRIAL OF ORAL RETROVIR IN PATIENTS WITH AIDS OR ARC

艾滋病或 ARC 患者口服逆转录病毒的剂量频率试验

• 批准号: 3886090
• 负责人: STEPHEN B GREENBERG
• 金额: --
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3886090
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; drug administration rate /duration; drug administration routes; human immunodeficiency virus; human subject; zidovudine

The purpose of this study is: (1) to evaluate the pharmacokinetics of retrovir administered orally as 200 mg every 4 hours, 400 mg every 8 hours, and 600 MG every 12 hours in the treatment of patient with severe clinical and laboratory manifestations of HIV infection; (2) to compare the safety and tolerance of retrovir administered two, three and six times daily to these patients.

本研究的目的是：（1）评价 每4小时口服200 mg，每8小时口服400 mg， 600毫克每12小时一次治疗重症临床 HIV感染的实验室表现;（2）比较安全性 和耐受性的逆转录病毒给予两个，三个和六个每天， 这些病人。